The use of panel testing in familial breast and ovarian cancer.

Prapa M1, Solomons J2, Tischkowitz M1,3.

Author information

Abstract

Advances in sequencing technology have led to the introduction of panel testing in hereditary breast and ovarian cancer. While direct-to-consumer testing services have become widely available, the clinical validity of many of the genes on panel tests remains contentious and risk management guidelines are often lacking. This article gives an overview of advantages with panel testing as well as important challenges, including clinical translation of test results.